GlassScriptPhysician profile
Sara E Martos
NPI 1366799074
$4,371.21
in general payments reported to CMS, 2019-2025
39 companies · $911 in 2025
The $911 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $839 · 2022: $676 · 2023: $1,170 · 2024: $775 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,574 · Education: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,574.17 |
| Education | $281.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $726.62 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $379.96 | 2021-2025 | Opdivo, Eliquis, Opdualag |
| Astrazeneca Pharmaceuticals LP | $328.11 | 2021-2025 | Imfinzi, Enhertu, Tagrisso |
| Takeda Pharmaceuticals U.S.A., INC. | $287.05 | 2021-2025 | Ninlaro, Fruzaqla, Iclusig |
| Incyte Corporation | $201.03 | 2021-2025 | Jakafi |
| Amgen INC. | $183.16 | 2021-2023 | Lumakras |
| Abbvie INC. | $181.91 | 2021-2025 | |
| Glaxosmithkline, LLC. | $167.79 | 2023-2025 | Ojjaara |
| Lilly USA, LLC | $160.59 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $140.26 | 2021-2023 | Reblozyl, Pomalyst |
| Gilead Sciences, INC. | $135.14 | 2023 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $130.10 | 2021-2023 | Imbruvica |
| Boston Scientific Corporation | $124.13 | 2023 | |
| Pfizer INC. | $122.75 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $111.35 | 2021-2025 | Keytruda, Welireg |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Martos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.